In a report released on November 14, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback